What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Enhancer RNA: Function, Mechanism, and Detection Methods

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Enhancer RNA

Enhancers are cis-regulatory DNA elements that increase the transcription of target genes, often over large genomic distances. For decades, enhancer function was studied exclusively through their ability to recruit transcription factors and co-activators to chromatin. However, a major conceptual shift occurred with the discovery that enhancers themselves are transcribed, producing a class of non-coding RNAs termed enhancer RNAs (eRNAs). These transcripts are not merely byproducts of an open chromatin state; they participate actively in gene regulation, chromatin architecture, and the recruitment of transcriptional machinery.

What is Enhancer RNA?

Enhancer RNA (eRNA) is a class of non-coding RNA transcribed from enhancer regions by RNA polymerase II (Pol II). Unlike messenger RNAs (mRNAs), eRNAs are generally short (typically 0.5–2 kb), lack canonical splicing, are often polyadenylated poorly or not at all, and are expressed at low abundance. They are frequently, though not exclusively, produced bidirectionally from the enhancer core, yielding both sense and antisense transcripts. The defining feature of an eRNA is not its sequence but its genomic origin: it is synthesized from a validated enhancer element, often identified by chromatin signatures such as H3K27ac (acetylation of histone H3 at lysine 27) and H3K4me1 (monomethylation of histone H3 at lysine 4). The enhancer region is the genomic locus; the eRNA is its transcriptional output.

Historical Context and Discovery

The first hints that enhancers produce RNA came from genome-wide mapping studies in the late 2000s. Using chromatin immunoprecipitation followed by sequencing (ChIP-seq) to map Pol II binding, researchers observed that Pol II occupied thousands of intergenic and intragenic regions that did not correspond to annotated genes. Concurrently, global run-on sequencing (GRO-seq) revealed widespread transcription outside of gene bodies, including at enhancer-like elements. In 2010, two landmark studies formally identified eRNAs as transcripts originating from active enhancers in neuronal and macrophage cells. These studies showed that eRNA production correlates with enhancer activity and that stimulation of cells with signaling molecules induces eRNA synthesis at inducible enhancers before target gene activation. This temporal relationship suggested that eRNA transcription is an early event in enhancer activation, not a passive consequence of chromatin opening.

Biogenesis of Enhancer RNA

The biogenesis of eRNA shares core features with mRNA production but diverges in important regulatory and processing steps. Understanding this process requires knowledge of how Pol II initiates at enhancers, how transcription proceeds, and how the resulting transcripts are processed or degraded.

Transcription Initiation at Enhancers

Enhancer transcription is initiated by the same core machinery used at promoters. Sequence-specific transcription factors bind to the enhancer sequence and recruit co-activators such as p300/CBP, which deposit H3K27ac. These co-activators, in turn, recruit the Mediator complex and general transcription factors (GTFs) including TFIID, TFIIB, and TFIIH. Pol II is then loaded onto the DNA at a transcription start site (TSS) within the enhancer. Unlike promoters, enhancer TSSs often lack a canonical TATA box, relying instead on other core promoter elements such as the initiator (Inr) or downstream promoter element (DPE). The initiation event is frequently bidirectional: Pol II is recruited in opposite orientations, producing divergent transcription. This is analogous to bidirectional transcription at promoters, but at enhancers it is often more symmetrical and less regulated by promoter-proximal pausing.

Bidirectional Transcription and Processing

Once initiated, Pol II transcribes the enhancer template for a short distance—typically 0.5 to 2 kilobases—before terminating. The mechanism of termination is not fully defined but may involve the integrator complex, which cleaves nascent transcripts and promotes Pol II release. The resulting eRNAs are often unspliced and lack a 5′ cap or 3′ poly(A) tail, making them susceptible to rapid degradation by the nuclear exosome. However, some eRNAs are stabilized by the addition of a poly(A) tail, particularly those transcribed from enhancers that produce longer, unidirectional transcripts. The balance between stabilization and degradation is a key regulatory point: the half-life of most eRNAs is short (minutes), but a subset is stabilized in response to specific signals.

The processing of eRNA is also linked to chromatin state. The act of transcription itself deposits histone marks—for example, the histone chaperone SPT6 and the histone methyltransferase SETD2 deposit H3K36me3 during elongation—which can further remodel the enhancer. Thus, eRNA biogenesis is not a passive readout but an active participant in enhancer maturation.

Mechanisms of Enhancer RNA Function

The functional relevance of eRNAs has been established through loss-of-function experiments, but the molecular mechanisms by which they act are diverse and, in some cases, context-dependent. Four major mechanisms have been proposed: chromatin looping, interaction with transcription machinery, regulation of chromatin modifications, and acting as decoys for RNA-binding proteins.

Chromatin Looping and Enhancer-Promoter Interactions

One of the best-supported functions of eRNAs is the stabilization of enhancer-promoter chromatin loops. Enhancers regulate their target genes by physically contacting the promoter, bringing distal regulatory elements into proximity. This looping is mediated by architectural proteins such as CTCF and cohesin, but eRNAs appear to reinforce these interactions. The current model posits that eRNAs recruit or stabilize cohesin at enhancer loci. Cohesin is a ring-shaped complex that holds sister chromatids together and also mediates long-range DNA interactions. Depletion of eRNAs by RNA interference (RNAi) reduces cohesin occupancy at enhancers and diminishes enhancer-promoter contacts, as measured by chromosome conformation capture (3C) or Hi-C. For example, at the MYOD1 locus in muscle cells, eRNA knockdown disrupts the loop between the enhancer and the MYOD1 promoter, reducing gene expression. This mechanism is particularly important for genes that require long-range regulation, where the enhancer may be located hundreds of kilobases away from its target promoter. The distinction between enhancer and promoter is blurred here, as both elements participate in looping and both produce RNA.

Interaction with Transcription Machinery

eRNAs can directly modulate the activity of transcription factors and co-activators. One well-characterized example is the interaction between eRNAs and the Mediator complex. Mediator is a large multi-subunit complex that bridges transcription factors at enhancers with Pol II at promoters. Some eRNAs bind to the cyclin-dependent kinase 8 (CDK8) subunit of Mediator, altering its kinase activity and thereby affecting Pol II phosphorylation and transcriptional elongation. In other contexts, eRNAs interact with the negative elongation factor (NELF), a complex that pauses Pol II at promoters. By sequestering NELF, eRNAs relieve promoter-proximal pausing and promote productive elongation. This mechanism has been demonstrated at immediate-early genes in macrophages, where eRNA production from inducible enhancers is required for the release of paused Pol II at target gene promoters. The eRNA thus acts as a molecular sponge, titrating away an inhibitory factor.

Regulation of Chromatin Modifications

eRNAs also influence the chromatin environment at enhancers and promoters. They can recruit histone-modifying enzymes to specific loci. For instance, the histone acetyltransferase p300 is recruited to enhancers in part through its interaction with eRNAs. This creates a positive feedback loop: eRNA production leads to further H3K27ac deposition, which maintains enhancer activity. Conversely, eRNAs can recruit histone demethylases such as LSD1 to remove repressive marks like H3K9me2, thereby maintaining an open chromatin state. In some cases, eRNAs guide the deposition of H3K4me1, a hallmark of poised enhancers, by interacting with the MLL3/MLL4 complex. These chromatin-modifying activities are not mutually exclusive; a single eRNA may recruit multiple factors depending on the cellular context.

A fourth proposed mechanism involves eRNAs acting as decoys for RNA-binding proteins (RBPs) that would otherwise repress transcription. For example, the RBP NONO binds to eRNAs at certain enhancers and is sequestered away from target gene promoters, preventing NONO-mediated repression. This decoy model is conceptually similar to the NELF sequestration described above but expands the repertoire of eRNA targets to include a broader class of regulatory proteins.

Evidence for Enhancer RNA Function

The claim that eRNAs are functional, rather than transcriptional noise, rests on a body of experimental evidence from multiple complementary approaches. These include loss-of-function studies, CRISPR-based perturbations, and correlative analyses that link eRNA expression to enhancer activity.

Loss-of-Function Studies

The most direct evidence for eRNA function comes from knockdown experiments. Small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) targeting eRNA transcripts—but not the enhancer DNA itself—have been used to deplete eRNAs in cultured cells. In a classic study at the FOXC1 locus in breast cancer cells, siRNA-mediated knockdown of eRNAs reduced FOXC1 mRNA levels by 50–70%, without altering the chromatin state at the enhancer. Similar results were obtained for eRNAs at the MYOD1 locus, the p53 target gene CDKN1A, and the estrogen receptor (ER)-regulated gene TFF1 in MCF-7 breast cancer cells. In each case, eRNA depletion reduced target gene expression, demonstrating that the transcript, not the act of transcription, is required for full enhancer activity. Importantly, these knockdowns are specific: they do not affect the transcription of the enhancer itself, only the stability of the eRNA, yet they phenocopy enhancer deletion.

CRISPR-Based Perturbations

CRISPR-Cas9 has enabled more precise perturbations of eRNA loci. Two approaches are commonly used. First, CRISPR interference (CRISPRi) uses a catalytically dead Cas9 (dCas9) fused to a transcriptional repressor such as KRAB to silence eRNA transcription at the DNA level. This approach has been applied genome-wide to identify enhancers whose eRNA production is required for cell proliferation. Second, CRISPR-Cas9 can be used to delete the eRNA transcription start site while leaving the transcription factor binding sites intact. This distinguishes the role of the eRNA transcript from the role of the enhancer DNA. In a study of the ARID1B enhancer, deletion of the eRNA TSS abolished eRNA production and reduced ARID1B expression by 40%, even though the enhancer remained bound by transcription factors. These experiments demonstrate that eRNA transcription is functionally separable from enhancer DNA sequence.

Correlative and Functional Studies

Genome-wide analyses have shown that eRNA expression correlates strongly with enhancer activity and target gene expression. In the FANTOM5 consortium data, eRNA levels at active enhancers predict the expression of nearby genes better than histone marks alone. This correlation has been exploited to identify active enhancers in a cell-type-specific manner. However, correlation is not causation, and the functional studies described above are essential to establish causality. A particularly powerful approach combines correlative genomics with functional validation: candidate eRNAs identified by GRO-seq are tested in high-throughput CRISPRi screens to determine which are required for gene expression. These screens have revealed that a substantial fraction of eRNAs are functional, but also that many are dispensable, suggesting that eRNA function is context-dependent.

Methods to Study Enhancer RNA

Detecting eRNAs is technically challenging because they are short, unstable, and often expressed at low levels. Several methods have been developed to overcome these obstacles, each with distinct strengths and limitations.

Global Run-On Sequencing (GRO-seq)

GRO-seq is a technique that maps the position of engaged RNA polymerases genome-wide. Cells are permeabilized, and transcription is allowed to resume in the presence of labeled nucleotides (typically 5-bromouridine 5′-triphosphate, Br-UTP). Nascent RNA is then immunoprecipitated with an anti-Br-UTP antibody, converted to cDNA, and sequenced. Because GRO-seq captures RNA that is being actively transcribed at the moment of cell lysis, it detects short-lived transcripts like eRNAs that would be missed by steady-state RNA-seq. The key advantage of GRO-seq is its ability to identify transcription start sites and directionality, making it ideal for detecting bidirectional eRNA transcription. A related method, global nuclear run-on (GRO) with a nuclear run-on buffer containing 0.5% sarkosyl, releases paused Pol II and allows detection of all engaged polymerases.

Precision Run-On Sequencing (PRO-seq)

PRO-seq is a higher-resolution variant of GRO-seq. Instead of labeling all nucleotides, PRO-seq uses biotinylated nucleotide triphosphates (biotin-NTPs) that are incorporated only at the 3′ end of the growing RNA chain. This allows mapping of Pol II position at single-nucleotide resolution. PRO-seq is particularly useful for identifying the exact TSSs of eRNAs and for detecting promoter-proximal pausing. The protocol involves nuclear isolation, run-on in the presence of biotin-NTPs, RNA fragmentation, streptavidin pull-down, and library preparation. The increased resolution comes at the cost of lower yield, requiring more starting material (typically 1–10 million cells).

Cap Analysis of Gene Expression (CAGE)

CAGE is a method that captures the 5′ ends of capped RNAs. It relies on the selective capture of the 7-methylguanosine cap using a cap-trapping procedure, followed by high-throughput sequencing of the first 20–30 nucleotides. Because eRNAs are often uncapped, CAGE may underrepresent them. However, a subset of eRNAs is capped, and CAGE has been used extensively by the FANTOM consortium to annotate enhancer activity across hundreds of cell types. The advantage of CAGE is its quantitative nature and its ability to identify TSSs with high precision. The disadvantage is that it requires a 5′ cap, which many eRNAs lack, and it does not provide information about the direction or extent of transcription.

Single-Cell Approaches

The methods described above are population-based and average eRNA signals across thousands of cells. Single-cell approaches are emerging to study eRNA heterogeneity. Single-cell RNA-seq (scRNA-seq) can detect eRNAs, but their low abundance and short half-life make them difficult to capture. More promising is single-cell ATAC-seq (assay for transposase-accessible chromatin) combined with RNA detection, which can correlate chromatin accessibility at enhancers with eRNA expression in the same cell. Additionally, single-molecule RNA fluorescence in situ hybridization (RNA-FISH) can visualize individual eRNA molecules at their site of transcription, providing spatial and temporal information. RNA-FISH uses multiple short fluorescently labeled probes that hybridize to the eRNA, allowing detection of single transcripts as diffraction-limited spots. This approach has revealed that eRNA transcription is stochastic and often occurs in bursts.

The table below summarizes the key features of the major eRNA detection methods.

Method	Principle	Detects	Resolution	Key Advantage	Key Limitation
GRO-seq	Run-on with Br-UTP	Engaged Pol II	~100 bp	Captures unstable eRNAs	Requires permeabilized cells
PRO-seq	Run-on with biotin-NTP	Engaged Pol II	Single nucleotide	Exact TSS mapping	Lower yield, more input needed
CAGE	5′ cap capture	Capped transcripts	Single nucleotide	Quantitative TSS identification	Misses uncapped eRNAs
RNA-FISH	Probe hybridization	Individual RNA molecules	Single molecule	Spatial localization	Low throughput, limited multiplexing
scRNA-seq	Single-cell cDNA amplification	All poly(A) RNA	Cell level	Cell-type specificity	Poor capture of short eRNAs

Enhancer RNA in Development and Disease

The regulatory roles of eRNAs are not restricted to cultured cells; they operate in vivo during development and are frequently dysregulated in disease.

Developmental Gene Regulation

During development, enhancers are the primary drivers of cell-type-specific gene expression. eRNAs are produced at many developmental enhancers and are required for proper differentiation. In embryonic stem cells (ESCs), eRNAs at pluripotency-associated enhancers are transcribed at high levels, and their knockdown impairs the expression of OCT4 (also known as POU5F1), SOX2, and NANOG. During neuronal differentiation, eRNAs are induced at activity-dependent enhancers in response to calcium signaling, and they are required for the expression of immediate-early genes such as FOS and EGR1. In the developing limb, eRNAs at SHH enhancers are expressed in a spatiotemporal pattern that mirrors SHH expression, and their disruption leads to limb malformations in mouse models. These examples illustrate that eRNAs are integral to the gene regulatory networks that drive development.

Enhancer RNA in Cancer and Other Diseases

Cancer is characterized by widespread enhancer dysregulation, and eRNAs are emerging as both drivers and biomarkers of malignancy. Oncogenic transcription factors such as MYC and estrogen receptor (ER) bind to enhancers and induce eRNA production. In ER-positive breast cancer, eRNAs at ER-bound enhancers are required for the expression of estrogen-responsive genes, and their levels correlate with patient prognosis. In prostate cancer, the androgen receptor (AR) induces eRNAs at AR-regulated enhancers, and one such eRNA, ARLNC1, stabilizes the AR transcript itself, creating a positive feedback loop that drives tumor growth. Beyond cancer, eRNAs have been implicated in neurological disorders, cardiovascular disease, and inflammatory conditions. For example, eRNAs at cytokine-inducible enhancers in macrophages are required for the full expression of inflammatory genes, and their dysregulation contributes to chronic inflammation.

The potential of eRNAs as biomarkers is an active area of investigation. Because eRNA expression is highly cell-type-specific and correlates with enhancer activity, eRNAs in plasma or tumor tissue could indicate the activation state of specific signaling pathways. However, their short half-life and low abundance make detection in clinical samples challenging, and no eRNA-based diagnostic is currently approved.

Common Pitfalls and Misconceptions

The study of eRNAs is fraught with technical and conceptual pitfalls. Understanding these is essential for interpreting the literature and designing experiments.

Distinguishing eRNA from Other Non-Coding RNAs

A common error is to conflate eRNAs with other classes of non-coding RNAs, particularly long non-coding RNAs (lncRNAs). The distinction is operational, not absolute: an eRNA is defined by its genomic origin at an enhancer, whereas a lncRNA is defined by its length (>200 nt) and lack of protein-coding potential. Some lncRNAs are transcribed from enhancers and are therefore also eRNAs. For example, lincRNA-p21 is a lncRNA that is transcribed from a p53-bound enhancer and functions as an eRNA. The practical takeaway is that the term "eRNA" describes a genomic context, not a distinct biochemical class. Additionally, eRNAs should not be confused with promoter-associated RNAs or antisense transcripts, which originate from different genomic features. The enhancer in transcription context is distinct from promoter transcription, though both involve Pol II.

Functional vs. Non-Functional eRNAs

Not all eRNAs are functional. Many enhancers produce eRNAs that are dispensable for target gene expression, as shown by CRISPRi screens where only a fraction of eRNA-producing enhancers affect gene expression when silenced. The assumption that all eRNAs are functional is a misconception. The field has moved toward a model where eRNA function is context-dependent: an eRNA may be required in one cell type or condition but not another. Moreover, the act of transcription itself—independent of the RNA product—can be functional by promoting chromatin accessibility or recruiting histone modifiers. Thus, experiments that perturb eRNA transcription at the DNA level (e.g., CRISPRi) cannot distinguish between the role of the transcript and the role of transcription. Only experiments that deplete the RNA without affecting transcription (e.g., siRNA) can establish transcript-specific functions.

Technical Challenges in Detection

Several technical artifacts can confound eRNA studies. First, eRNAs are often detected by RNA-seq, but standard library preparation with poly(A) selection will miss most eRNAs because they lack poly(A) tails. Using ribosomal RNA depletion instead of poly(A) selection is essential. Second, eRNAs are frequently misannotated as intergenic or antisense transcripts in RNA-seq analyses, leading to their exclusion from downstream analysis. Third, the short half-life of eRNAs means that steady-state RNA levels may not reflect transcription rates; nuclear run-on methods are more reliable. Fourth, contamination of RNA preparations with genomic DNA can produce false eRNA signals, particularly for intronic or intergenic regions. Treatment with DNase I is critical. Finally, eRNA detection by PCR requires careful primer design to avoid amplifying genomic DNA, and reverse transcriptase-negative controls should be included.

Summary and Key Takeaways

Enhancer RNAs are a class of non-coding transcripts produced from enhancer regions by RNA polymerase II. They are typically short, bidirectional, and unstable, yet they play significant roles in gene regulation. The primary mechanisms of eRNA function include stabilizing enhancer-promoter chromatin loops, interacting with transcription machinery such as Mediator and NELF, recruiting chromatin-modifying enzymes, and acting as decoys for RNA-binding proteins. Evidence for eRNA function comes from knockdown studies, CRISPR-based perturbations, and genome-wide correlations. Detection requires specialized methods such as GRO-seq, PRO-seq, CAGE, and single-cell approaches, each with distinct advantages and limitations. eRNAs are important in development and are dysregulated in diseases including cancer, where they may serve as biomarkers. However, not all eRNAs are functional, and technical artifacts can confound their study.

Frequently Asked Questions

What is enhancer RNA?

Enhancer RNA (eRNA) is a non-coding RNA transcribed from an enhancer region by RNA polymerase II. It is typically short (0.5–2 kb), often bidirectional, and frequently lacks a poly(A) tail. Its defining feature is its genomic origin, not its sequence or structure.

What is the function of enhancer RNA?

eRNAs regulate gene expression by several mechanisms: stabilizing enhancer-promoter chromatin loops, interacting with transcription factors and co-activators such as Mediator, sequestering negative elongation factors like NELF, recruiting histone-modifying enzymes, and acting as decoys for RNA-binding proteins. Their function is context-dependent and not all eRNAs are functional.

How is enhancer RNA detected?

eRNAs are detected using methods that capture nascent or unstable RNA, including GRO-seq, PRO-seq, CAGE, and RNA-FISH. Standard RNA-seq with poly(A) selection is inadequate because most eRNAs lack poly(A) tails. Ribosomal RNA depletion and nuclear run-on approaches are preferred.

Are enhancer RNAs protein-coding?

No. eRNAs are non-coding RNAs. They do not encode proteins and are not translated. They function as RNA molecules within the nucleus.

Do all enhancers produce enhancer RNA?

No. Only a subset of enhancers produces eRNAs. Active enhancers are more likely to produce eRNAs than poised or inactive enhancers, but eRNA production is not a universal feature of enhancer activity. The presence of eRNA is often used as a marker of enhancer activity, but its absence does not necessarily mean the enhancer is inactive.

Can enhancer RNA be used as a biomarker?

Potentially, yes. eRNA expression is highly cell-type-specific and correlates with enhancer activity and target gene expression. In cancer, eRNA levels at oncogenic enhancers have been associated with patient prognosis. However, their short half-life and low abundance make clinical detection challenging, and no eRNA-based biomarker is currently in clinical use.

What is the difference between enhancer RNA and long non-coding RNA?

The distinction is operational. A long non-coding RNA (lncRNA) is defined as a non-coding transcript longer than 200 nucleotides. An eRNA is defined by its genomic origin at an enhancer. Some lncRNAs are transcribed from enhancers and are therefore both lncRNAs and eRNAs. The terms are not mutually exclusive; they describe different aspects of the same transcript.

Key Takeaways

Enhancer RNAs are non-coding transcripts produced from enhancer regions by RNA polymerase II, typically short, bidirectional, and unstable.
eRNAs function by stabilizing enhancer-promoter loops, interacting with transcription machinery, recruiting chromatin modifiers, and sequestering RNA-binding proteins.
Functional evidence comes from siRNA knockdown, CRISPRi, and deletion of eRNA transcription start sites, which reduce target gene expression.
Detection requires specialized methods like GRO-seq, PRO-seq, CAGE, and RNA-FISH; standard poly(A)-selected RNA-seq is insufficient.
eRNAs play roles in development and are dysregulated in cancer, where they may serve as biomarkers.
Not all eRNAs are functional, and the act of transcription can be important independent of the RNA product.
Technical pitfalls include misannotation, genomic DNA contamination, and failure to distinguish eRNAs from other non-coding RNAs.